• Daniel P Nussbaum, Paul J Speicher, Brian C Gulack, Asvin M Ganapathi, Brian R Englum, David G Kirsch, Douglas S Tyler, and Dan G Blazer.
• Departments of *Surgery †Radiation Oncology, and ‡Pharmacology and Cancer Biology, Duke University, Durham, NC.
• Ann. Surg. 2015 Jul 1; 262 (1): 163-70.

ObjectiveTo evaluate long-term survival among patients undergoing radiation therapy (RT), followed by surgical resection of retroperitoneal sarcomas (RPS).BackgroundDespite a lack of level 1 evidence supporting neoadjuvant RT for RPS, its use has increased substantially over the past decade.MethodsThe 1998-2011 National Cancer Data Base was queried to identify patients who underwent resection of RPS. Subjects were grouped by use of neoadjuvant RT. Perioperative variables and outcomes were compared. Multivariable logistic regression was performed to assess predictors of neoadjuvant RT. Groups were propensity matched using a 2:1 nearest neighbor algorithm and short-term outcomes were compared. Finally, long-term survival was evaluated using the Kaplan-Meier method, with comparisons based on the log-rank test.ResultsA total of 11,324 patients were identified. Neoadjuvant RT was administered to 696 patients (6.1%). During the study period, preoperative RT use increased from 4% to nearly 15%. Male sex, tumor size larger than 5 cm, treatment at an academic/research program, and higher tumor grade all predicted neoadjuvant RT administration. After propensity matching, the only difference in baseline characteristics was the use of neoadjuvant chemotherapy. Although neoadjuvant RT was associated with a higher rate of negative margins (77.5% vs 73.0%; P = 0.014), there was no corresponding improvement in 5-year survival (53.2% vs 54.2%; P = 0.695).ConclusionsDespite the increasing use of neoadjuvant RT for patients with RPS, the survival benefit associated with this treatment modality remains unclear. Continued investigation is needed to better define the role of RT among patients with RPS.

16 keywords...

hide…